Methodology:

Data on patients with low or intermediate-1 risk MDS will be collected prospectively at diagnosis and at 6-months intervals after diagnosis. The data will be gathered by eleven existing national MDS Registries that are represented within the LeukemiaNet MDS Working Party and will be combined in one central European Database. Data analyses will be conducted by the Data Management Centre after every 400 patients included in the European Registry and at the end of the follow-up period.

Number of Patients & Centres Eleven hematology centres in eleven different countries (Austria, Czech Republic, France, Germany, Greece, Italy, Netherlands, Rumania, Spain, Sweden and United Kingdom) will participate as referral centres in this Registry. The recruitment target is 1000.

Population:

The study population will consist of newly diagnosed patients with IPSS low- or intermediate-1 risk myelodysplastic syndrome.

Study Duration:

The enrollment time will be 12 months. The follow-up period will be 2 years.

Clinic

Inclusion Criteria:

• Age > 18 years.
• Newly diagnosed patient (within 3 months from the date of the diagnostic bone marrow aspirate).
• MDS classified according to WHO criteria (2001).
• IPSS Risk group Low or Intermediate-1 .
• Able and willing to provide the written informed consent.

Exclusion Criteria:

• Age <18 years
• Patient unwilling or unable to give consent
• intermediate-2 or high risk MDS, or in case the IPSS group cannot be defined ≥ 5% bone marrow blasts.
• secondary/therapy-related MDS.